[go: up one dir, main page]

FR2394292A1 - Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals - Google Patents

Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals

Info

Publication number
FR2394292A1
FR2394292A1 FR7605881A FR7605881A FR2394292A1 FR 2394292 A1 FR2394292 A1 FR 2394292A1 FR 7605881 A FR7605881 A FR 7605881A FR 7605881 A FR7605881 A FR 7605881A FR 2394292 A1 FR2394292 A1 FR 2394292A1
Authority
FR
France
Prior art keywords
minerals
combination
compsn
neoplastic
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7605881A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRAUSZ LESLIE
Original Assignee
KRAUSZ LESLIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KRAUSZ LESLIE filed Critical KRAUSZ LESLIE
Priority to FR7605881A priority Critical patent/FR2394292A1/en
Publication of FR2394292A1 publication Critical patent/FR2394292A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A two-part treatment of cancer comprises administering separately, but simultaneously, a cinchoma alkaloid bark extract (I) and a combination of multi-vitamins and minerals (II). In a pref. mode of administration, (I) is injected into the animal having the tumour while (II) is taken p.o.
FR7605881A 1976-03-02 1976-03-02 Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals Withdrawn FR2394292A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7605881A FR2394292A1 (en) 1976-03-02 1976-03-02 Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7605881A FR2394292A1 (en) 1976-03-02 1976-03-02 Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals

Publications (1)

Publication Number Publication Date
FR2394292A1 true FR2394292A1 (en) 1979-01-12

Family

ID=9169841

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7605881A Withdrawn FR2394292A1 (en) 1976-03-02 1976-03-02 Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals

Country Status (1)

Country Link
FR (1) FR2394292A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755633A1 (en) * 1995-07-28 1997-01-29 Herbert Schlachter Two phases preparation
FR2858619A1 (en) * 2003-08-08 2005-02-11 Aventis Pharma Sa New 4-substituted quinoline derivatives are useful to treat bacterial infections in humans
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755633A1 (en) * 1995-07-28 1997-01-29 Herbert Schlachter Two phases preparation
WO1997004668A2 (en) * 1995-07-28 1997-02-13 Herbert Schlachter Two-stage preparation
WO1997004668A3 (en) * 1995-07-28 1997-06-12 Herbert Schlachter Two-stage preparation
US6471969B1 (en) 1995-07-28 2002-10-29 Herbert Schlachter Two-phase preparation
FR2858619A1 (en) * 2003-08-08 2005-02-11 Aventis Pharma Sa New 4-substituted quinoline derivatives are useful to treat bacterial infections in humans
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
PL309033A1 (en) Method of activating photosensibilisers
MY112405A (en) Method of tumer treatment.
HU890950D0 (en) Process for decreasing the harmful side-effects of cancer therapy
HK1046093B (en) Docetaxel in combination with rhumab her2 for the treatment of cancers
DK642587D0 (en) INSULIN PREPARATION
CA982478A (en) Orally administered drug composition for therapy in the treatment of narcotic drug addiction
MY116474A (en) Potentiation of temozolomide in human tumour cells
ES8507567A1 (en) Stabilized gamma globulin concentrate.
SE8204585D0 (en) ERGOPEPTIN DERIVATIVES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE AND THEIR USE IN THERAPEUTIC TREATMENT
FR2394292A1 (en) Synergistic anti-neoplastic compsn. - comprises injecting cinchona alkaloid(s) while taking orally a combination of vitamin(s) and minerals
ATE313334T1 (en) TREATING TUMORS WITH PHOTODYNAMIC THERAPY
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
EP0338679A3 (en) Tumour necrosis factor in the treatment of bladder cancer
DK0594739T3 (en) cancer Treatment
ES2012547A6 (en) Use of metalloporphyrins to reverse the toxic effect of tumor therapy.
AU4042795A (en) Treatment of non-small cell lung carcinoma
ES2019713A6 (en) Treatment of malignant tumors with 8-chloroadenosine 3',5'-cyclic phosphate, 8-aminoadenosine 3',5'-cyclic phosphate and preparation thereof.
Smith et al. Preliminary report of the use of levamisole in the treatment of bladder cancer
FR2164900A1 (en) Carcinostatic immunogammaglobulin prodn - from blood of animals injected with human cancer-cells
DE3485282D1 (en) COMPOSITION FOR TREATING BOUGIC TUMORS, ESPECIALLY IN ANIMALS.
SU1540072A1 (en) METHOD OF TREATING DIRECT GUT CANCER
RU5065975A (en) METHOD OF TREATMENT OF MALIGNANT TUMORS
Gibson The centenary of Shoma Morita.
Forsman Reserpine treatment of certain depressive conditions: Case report, treatment, and possible mechanisms of action.
Appel et al. The Lund Alcohol Study: Some preliminary results after 1 year of treatment.

Legal Events

Date Code Title Description
ST Notification of lapse